Clinical Trials
11 trialsNCT01756118 2023-02-16
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Goethe University
Phase 1 Completed
NCT01482156 2020-12-21
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00620594 2020-12-09
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT01195376 2020-12-09
A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01285466 2020-12-09
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Phase 1 Completed
NCT01471847 2020-12-09
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
Novartis
Phase 1 Completed
NCT01634061 2020-12-09
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Novartis
Phase 1 Completed
NCT01337765 2020-10-09
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Pfizer
Phase 1 Completed
NCT01248494 2016-07-25
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT01658436 2016-05-02
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Novartis
Phase 2 Completed
NCT01343498 2015-05-01
Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed